Moloney Securities Asset Management LLC Has $610,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Moloney Securities Asset Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 37.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,086 shares of the biopharmaceutical company’s stock after acquiring an additional 5,785 shares during the period. Moloney Securities Asset Management LLC’s holdings in Pfizer were worth $610,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $29,000. Quarry LP acquired a new position in shares of Pfizer during the 2nd quarter worth $31,000. Financial Connections Group Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer during the 1st quarter worth $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Trading Down 2.3 %

NYSE PFE opened at $27.35 on Thursday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The business’s 50-day moving average price is $28.96 and its two-hundred day moving average price is $28.64. The firm has a market capitalization of $154.98 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.14%. Pfizer’s payout ratio is 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.